FibroBiologics Secures Regulatory Approval for Phase 1/2 Trial of CYWC628 in Diabetic Foot Ulcers
核心洞察
FibroBiologics (搜索) received Human Research Ethics Committee approval in Australia to initiate a Phase 1/2 clinical trial of CYWC628, an investigational allogeneic fibroblast (搜索) cell-based therapy for refractory diabetic foot ulcers (搜索).
The multicenter, randomized trial will enroll 120 patients across 10 Australian sites to evaluate safety, tolerability, and efficacy of topically administered CYWC628 over 12 weeks of treatment.
Preclinical data suggest CYWC628 may significantly accelerate wound healing compared to currently available treatments, potentially addressing a significant unmet need in chronic wound management.
FibroBiologics (搜索), Inc. (Nasdaq: FBLG) has received both public and private Human Research Ethics Committee (HREC) approvals in Australia for a Phase 1/2 clinical trial evaluating CYWC628 for the treatment of refractory diabetic foot ulcers (搜索). This regulatory milestone enables enrollment of 120 patients at 10 sites across Australia and represents a significant step forward for the Houston-based clinical-stage biotechnology company's fibroblast (搜索)-based therapeutic platform.
With the HREC approval and Therapeutics Goods Administration (TGA) filing now complete, FibroBiologics (搜索) has secured all necessary regulatory approvals and submitted all required filings to proceed with the clinical trial. Southern Star Research (搜索), a leading full-service Australian contract research organization with Asia-Pacific coverage, will manage all aspects of the CYWC628 trial from start to finish.
Trial Design and Objectives
The approved clinical trial is a prospective, multicenter, randomized study designed to evaluate the safety, tolerability, and efficacy of CYWC628, an investigational topically administered allogeneic fibroblast (搜索) cell-based therapy for wound healing. Participants will receive up to 12 weeks of treatment using either standard of care plus a low or high dose of CYWC628, or standard of care alone.
The trial will assess wound healing outcomes, efficacy of response, and safety parameters through regular clinical and imaging evaluations. An interim analysis will be conducted after a predefined number of participants complete six weeks of treatment to assess primary safety and efficacy endpoints.
Therapeutic Potential and Unmet Need
Preclinical data suggest CYWC628 may significantly accelerate wound healing compared to currently available treatments. The study is expected to provide key clinical data supporting CYWC628 as a novel, fibroblast (搜索)-based cell therapy aimed at addressing a significant unmet need in chronic wound management.
"We're excited to receive HREC approvals for our Phase 1/2 trial in refractory diabetic foot ulcers (搜索)," said Pete O'Heeron, Founder and CEO of FibroBiologics (搜索). "This is an important milestone. It moves our fibroblast (搜索)-based platform into real-world clinical testing. What we learn from this study could potentially help unlock a new class of cell therapies for chronic wounds (搜索)-an area where patients have been underserved for far too long."
Company Platform and Pipeline
FibroBiologics (搜索) is developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast (搜索) cells and fibroblast-derived materials. The company holds 270+ US and internationally issued patents and patents pending across various clinical pathways, including wound healing, multiple sclerosis (搜索), disc degeneration, psoriasis (搜索), orthopedics, human longevity, and cancer (搜索).
Lloyd Prescott, CEO of Southern Star Research (搜索), expressed enthusiasm for the partnership: "We are honored to continue our partnership with FibroBiologics (搜索) whose leadership in cell therapy and regenerative medicine truly inspires us."
In addition to confirming safety and therapeutic potential, the study is expected to provide crucial clinical validation for FibroBiologics (搜索)' fibroblast (搜索)-based approach to treating chronic wounds (搜索), potentially establishing a new therapeutic paradigm for patients with refractory diabetic foot ulcers (搜索).